Abstract 2044P
Background
BSI are a frequent and severe complication in cancer. Recent changes in oncological treatment, supportive care and development of new antimicrobial therapies could have affected its epidemiology, management and outcomes. Our aim is to describe clinical and microbiological features, antibiotic therapy, outcomes and mortality-related risk factors of BSI in cancer patients.
Methods
We performed a retrospective, observational, unicentric study. Microbiologically-confirmed BSI episodes in cancer patients between January 2017 and December 2021 were collected. We analysed clinical and microbiological data, empirical antibiotic treatment (EAT) and outcomes. A binary logistic regression model was used to detect variables related to 7 and 30-days mortality. P values <0.05 were considered significant.
Results
438 episodes of BSI were documented in 362 patients. Most frequent neoplasms were pancreatobiliary (25.1%), colorectal (16.9%), lung (11.9%) and breast (9.1%) tumours. 78.1% were metastatic. 72.1% had received chemotherapy in the previous month. The most common sources of BSI were vascular catheters (26.9%), cholangitis (23.1%) and other abdominal infections (22.8%). Gram-negative bacteria (GNB) were isolated in 60.3% of cases and Gram-positive bacteria in 45.4%. Yeasts were isolated in 3.9% of cases. Most common organisms were E. coli (29.7%), Klebsiella spp. (15.1%), coagulase-negative staphylococcus (12.6%) and S. aureus (10.3%). Most used EAT was piperacillin/tazobactam (43.2%), followed by meropenem (18.3%), amoxicilin/clavulanic acid (16%) and vancomycin (14.8%). Adequate EAT was given to 76.3% of patients. Mortality at 7 and 30 days was 11.2% and 24.4%, respectively. Statistical analysis showed lung cancer, respiratory source, yeasts and Pseudomonas spp. as independent risk factors for 7 and 20-days mortality.
Conclusions
BSI is a severe complication associated to elevated mortality in cancer patients. Most frequent sources of BSI are vascular catheters, cholangitis and abdominal infections. Most of them occur in patients with metastatic digestive tumours and are caused by GNB. Lung cancer, respiratory infections, isolation of yeasts and Pseudomonas spp. could imply a worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06